KIT and gastrointestinal stromal tumor: In addition, the dramatic anti-proliferative effects (Cell viability IC50s at day 6 were 3.5 nM for GIST48B, 3 nM for GIST54, and 6.5 nM for GIST226, respectively, via targeting cyclin D1 and YAP/TAZ expression in low dose of bortezomib (1–10 nM) (Supplementary Figure S2 and Figure 2B) have demonstrated that bortezomib effects are more pronounced against KIT-independent GIST cells in vitro-based study.